Evidence map›Paper›PMID 26604271›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2016

MicroRNA Profiles of Barrett's Esophagus and Esophageal Adenocarcinoma: Differences in Glandular Non-native Epithelium.

Jennifer Drahos, Katrin Schwameis, Linda D Orzolek, Haiping Hao, Peter Birner, Phillip R Taylor, Ruth M Pfeiffer, Sebastian F Schoppmann, Michael B Cook

Open access · bronzeAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Circulating microRNAs Expression as Prognosis Biomarker of Cholangiocarcinoma.Asian Pacific journal of cancer prevention : APJCP · 2026
    Article
  3. Article
  4. Article
  5. Apelin/APJ: Another Player in the Cancer Biology Network.International journal of molecular sciences · 2025
    Review
  6. Article
  7. miRNA profiling of esophageal adenocarcinoma using transcriptome analysis.Cancer biomarkers : section A of Disease markers · 2024
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Novel Screening Tests for Barrett's Esophagus.Current gastroenterology reports · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jennifer DrahosDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DDHS, Bethesda, Maryland. jennifer.drahos@nih.gov.
Katrin SchwameisDepartment of Surgery, Upper-GI-Service, CCC-GET Unit, Medical University of Vienna, Vienna, Austria.
Linda D OrzolekJohns Hopkins Medical Institutions Deep Sequencing and Microarray Core, Baltimore, Maryland.
Haiping HaoJohns Hopkins Medical Institutions Deep Sequencing and Microarray Core, Baltimore, Maryland.
Peter BirnerDepartment of Surgery, Upper-GI-Service, CCC-GET Unit, Medical University of Vienna, Vienna, Austria.
Phillip R TaylorDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DDHS, Bethesda, Maryland.
Ruth M PfeifferDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DDHS, Bethesda, Maryland.
Sebastian F SchoppmannDepartment of Surgery, Upper-GI-Service, CCC-GET Unit, Medical University of Vienna, Vienna, Austria.
Michael B CookDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DDHS, Bethesda, Maryland.
National Cancer Institute · USMedical University of Vienna · ATJohns Hopkins University · US

Funding

Upper Gastrointestinal Cancer StudiesZIACP000185 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ABNET, CHRISTIAN · 2009 to 2025
$25.6M
Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

backgroundThe tissue specificity and robustness of miRNAs may aid risk prediction in individuals diagnosed with Barrett's esophagus. As an initial step, we assessed whether miRNAs can positively distinguish esophageal adenocarcinoma from the precursor metaplasia Barrett's esophagus.

methodsIn a case-control study of 150 esophageal adenocarcinomas frequency matched to 148 Barrett's esophagus cases, we quantitated expression of 800 human miRNAs in formalin-fixed paraffin-embedded tissue RNA using NanoString miRNA v2. We tested differences in detection by case group using the χ(2) test and differences in expression using the Wilcoxon rank-sum test. Bonferroni-corrected statistical significance threshold was set at P < 6.25E-05. Sensitivity and specificity were assessed for the most significant miRNAs using 5-fold cross-validation.

resultsWe observed 46 distinct miRNAs significantly increased in esophageal adenocarcinoma compared with Barrett's esophagus, 35 of which remained when restricted to T1b and T2 malignancies. Three miRNAs (miR-663b, miR-421, and miR-502-5p) were detected in >80% esophageal adenocarcinoma, but <20% of Barrett's esophagus. Seven miRNAs (miR-4286, miR-630, miR-575, miR-494, miR-320e, miR-4488, and miR-4508) exhibited the most extreme differences in expression with >5-fold increases. Using 5-fold cross-validation, we repeated feature (miR) selection and case-control prediction and computed performance criteria. Each of the five folds selected the same top 10 miRNAs, which, together, provided 98% sensitivity and 95% specificity.

conclusionThis study provides evidence that tissue miRNA profiles can discriminate esophageal adenocarcinoma from Barrett's esophagus. This large analysis has identified miRNAs that merit further investigation in relation to pathogenesis and diagnosis of esophageal adenocarcinoma. IMPACT: These candidate miRNAs may provide a means for improved risk stratification and more cost-effective surveillance.

Indexed as

AdenocarcinomaBarrett EsophagusDisease ProgressionEsophageal NeoplasmsHumansMicroRNAsMicroRNAs

Identifiers

PMID26604271
PMCPMC4779694
OpenAlexW2175360882

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.